Author + information
- Daniele Gemma1,
- Raul Moreno1,
- Mariano Larman2,
- Rui Campante Teles3,
- Lino Patricio4,
- Eduardo Molina5,
- Vasco Gama Ribeiro6,
- Bruno Garcia del Blanco7,
- Manuel Sancho Jaldon8,
- Guillermo Galeote1,
- Santiago Jimenez Valero1,
- Angel Sanchez Recalde1,
- Ines Ponz de Antonio1 and
- Jose Lusi Lopez-Sendon1
- 1University Hospital La Paz, Madrid, Spain
- 2Policlínica Guipuzkoa, San Sebastian, Spain
- 3Hospital Santa Cruz, Lisboa, Portugal
- 4Centro Hospitalar de Lisboa Central, Lisboa, Portugal
- 5Hospital Virgen de las Nieves, Granada, Spain
- 6Centro Hospitalar de Vila Nova de Gaia, Oporto, Portugal
- 7Hospital Vall de Hebrón, Barcelona, Spain
- 8Hospital Puerta del Mar, Cadiz, Spain
LotusTM Valve (Boston Scientific) is a second generation fully retrievable and repositionable transcatheter aortic valve prosthesis. The aim of this study is to report the initial multicentric experience with Lotus Valve System for treatment of patients with severe aortic stenosis.
Observational study that reports the results to hospital discharge of Lotus valve implantation in 5 centers in Spain and 3 in Portugal between March 2014 and April 2016.
102 patients (mean age 80.4 ± 6.1 years, 52.9% women and STS score 5.2% ± 3.3%) with severe symptomatic aortic stenosis (mean aortic valve area 0.66 ± 0.17 cm2, aortic gradients 74.3 / 45.6 mmHg) were included. The valve was successfully implanted in 100 patients (98%), with significant improvement in both peak and mean aortic valve gradients and with only one patient with moderate paravalvular regurgitation (figure). To hospital discharge, the mortality rate was 3,9% and the rate of stroke was 2,9% (2 cases of disabling strokes, 1 non disabling). No cases of valve embolization, ectopic valve deployment or additional valve implantation (valve-in-valve) was observed. 33 patients (32,3%) received a permanent pacemaker.
Lotus Valve System is effective and safe for treating patients with severe symptomatic aortic stenosis. Particularly, high lights the low rate of periprosthetic regurgitation and absence of complications like embolization or ectopic valve deployment of the prosthesis, at the expense of a high pacemaker implant.